A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
J Clin Invest. 2020 May 1;130(5):2570-2586. doi: 10.1172/JCI133055.
J Clin Invest. 2020.
PMID: 32017708
Free PMC article.